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Abstract
Background: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. It is a highly
heterogeneous disease, and can be divided roughly into indolent and progressive stages based on classic clinical
markers. Immunoglobin heavy chain variable region (IgVH) mutational status was found to be associated with
patient survival outcome, and biomarkers linked to the IgVH status has been a focus in the CLL prognosis research
field. However, biomarkers highly correlated with IgVH mutational status which can accurately predict the survival
outcome are yet to be discovered.
Results: In this paper, we investigate the use of gene co-expression network analysis to identify potential
biomarkers for CLL. Specifically we focused on the co-expression network involving ZAP70, a well characterized
biomarker for CLL. We selected 23 microarray datasets corresponding to multiple types of cancer from the Gene
Expression Omnibus (GEO) and used the frequent network mining algorithm CODENSE to identify highly
connected gene co-expression networks spanning the entire genome, then evaluated the genes in the co-
expression network in which ZAP70 is involved. We then applied a set of feature selection methods to further
select genes which are capable of predicting IgVH mutation status from the ZAP70 co-expression network.
Conclusions: We have identified a set of genes that are potential CLL prognostic biomarkers IL2RB, CD8A, CD247,
LAG3 and KLRK1, which can predict CLL patient IgVH mutational status with high accuracies. Their prognostic
capabilities were cross-validated by applying these biomarker candidates to classify patients into different outcome
groups using a CLL microarray datasets with clinical information.
Background
Chronic lymphocytic leukemia (CLL), also called B-cell
CLL, is the most common type of leukemia, which
mainly affects adults. Nearly 100,000 Americans live
with CLL, most of them over fifty years old. Rates of
CLL incidence are increasing, and there is no known
cure for the disease [1]. For patients diagnosed with
CLL, staging or classification systems such as the widely
adopted Rai and Binet staging systems can categorize
the patients into classes with different risk levels [2].
However, currently these systems still have difficulty in
discriminating indolent and progressive CLL. Specifi-
cally, some patients remain in the beginning or indolent
stage of the disease and do not require treatment, which
involves numerous undesirable side effect, for time peri-
ods of up to ten or more years [3,4]. In contrast, some
patients experience very aggressive disease in a short
time period, characterized by rapid white blood cell
doubling time, and requiring immediate treatment.
These differences delineate two distinct groups of
patients: indolent and progressive CLL. Those with the
non-progressive manifestation of the disease rarely need
treatment until the disease transforms into an aggressive
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Early determination of the CLL subtype is central to the
goal of providing evidence-based adaptive therapies [6].
Such adaptive therapies can decrease disease-related
mortality and increase quality of life. Several biomarkers
have proven helpful in supporting such disease staging
[4]. For example, the mutational status of IgVH genes
have been named in multiple studies as a biomarker for
CLL disease progression [5,7,8]. However, testing IgVH
mutation status is costly and is not readily available in
all clinical settings. Recently, cell membrane proteins
such as ZAP70 (Zeta-chain-associated protein kinase
70) and CD38 have been proposed as biomarkers for
CLL prognosis [5,9,10]. Positive ZAP70 or CD38 tests
have been shown to correlate with progressive CLL.
While the identification ofZ A P 7 0a n di t sp r o g n o s t i c
value represents progress toward more widespread and
accessible CLL staging, ZAP70 testing only yields defini-
tive results when conducted during later, symptomatic
phases of disease progression [11]. And CD38 was later
found to be an independent biomarker [12]. A more
desirable method would be to determine biomarkers or
phenotypic parameters that are able to definitively
determine the likelihood with which a patient may
develop rapid disease progression early in the pathophy-
siologic development of CLL. Thus researchers are still
searching for new CLL biomarkers as illustrated in
recent reports on correlations between LAG3 and LPL
level and the mutation status of IgVH genes in CLL
patients [13].
Given the preceding motivation to discover and utilize
more timely, effective, and accessible CLL biomarkers,
we have investigated the use of gene co-expression net-
work analysis to identify such prognostic factors. Gene
co-expression networks are established by connecting
genes with similar expressionp r o f i l e sa c r o s sag r o u po f
subjects or in multiple studies. The similarity of expres-
sion profiles is often measured by parameters such as the
Pearson correlation coefficients (PCC, -1 ≤ PCC ≤ 1),
with a PCC of 1 implying perfect correlation and PCC of
-1 being completely negative correlation. In a recent
study, by using the well-known breast cancer biomarkers
BRCA1 and BRCA2 as anchor genes, the authors were
able to discover a new breast cancer biomarker, HMMR,
whose expression profile highly correlates with those of
the two anchor genes [14].
In this project, we took a similar approach by studying
genes co-expressed with ZAP70 in multiple datasets.
Specifically, we selected 23 microarray datasets corre-
sponding to multiple types of cancers from the Gene
Expression Omnibus (GEO) and used the CODENSE
algorithm to identify highly connected gene co-expres-
sion network spanning the entire genome. We then nar-
rowed down the gene list in the co-expression networks
in which ZAP70 was involved by testing their capabil-
ities for predicting the IgVH status of the subjects using
various machine learning feature selection methods. The
workflow for this approach is summarized in Figure 1.
The biomarkers identified from the workflow were then
subjected to validation by testing their prognostic power
on another CLL microarray dataset with patients clinical
outcome information available.
Results
Identify genes in the co-expression network with ZAP70
using CODENSE
Using the CODENSE algorithm with the settings
described in the Methods section, we identified 44
highly connected co-expression networks (connectivity
ratio r > 0.4). Network 17 (shown in Figure 2, contain-
ing 51 genes) includes the well known CLL biomarker
ZAP70. Interestingly, another CLL biomarker CD38 is
also included in this network. Four genes CD8A, CD3G,
CD247 and CD3D, whose products are known to inter-
act with ZAP70, are also in this network. The GO-term
enrichment analysis using IPA (Ingenuity Pathway Ana-
lysis) revealed highly enriched biological functions
related to leukemia, such as cell growth and prolifera-
tion, hematological system development and function,
inflammatory response, and immunological disease.
(Figure 3).
Identify genes in the ZAP70 co-expression network with
differential expression levels between different IgVH
mutation groups in GDS1454 dataset
Among these 51 genes, we further selected genes whose
expression levels can predict IgVH mutation status using
the three steps outlined in the Method section.
Table 1 summarizes the genes in Network 17 with
p-values less than 0.05 and a mean expression fold
change greater than 1.5 (except for ZAP70) between
the IgVH unmutated and mutated groups using Stu-
dent’s t-tests. Out of the 51 genes in Network 17, 11
genes satisfied these criteria, with 10 genes up-regu-
lated in the IgVH unmutated group and one gene
down-regulated in the same group. It is worth noting
that although our selection criteria does not include
t h em o r ec o n s e r v a t i v em u l t i p l et - t e s tc o m p e n s a t i o n
methods such as Bonferroni test, out of the 12651
probesets in GDS1454, only 190 satisfied our criteria
with 122 up-regulated and 68 down-regulated, which
constitute a reasonable set of genes for further screen-
ing. In addition, in the GeneCards database, we identi-
fied 120 candidate genes, which products interact with
ZAP70. Out of the 120, 9 genes’ expression profiles
satisfied our selection criteria, with 4 of the 9 being
included in Network 17 (the names with circle in
Figure 2).
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mutational status
The preceding comparisons suggest that the co-expres-
sion network we have discovered is enriched with genes
that differentially expressed between the IgVH unmu-
t a t e dg r o u pa n dI g V H mutated group. In addition, since
these genes are all related to ZAP70, we focused on
selecting candidate biomarkers from those listed in
Table 1. We tested the predictive capacity of those 12
genes (11 genes identified from the above approach plus
ZAP70) relative to IgVH mutational status using a linear
classifier. For each gene, the test was carried out using a
cross-validation with 20% holdout of the samples,
repeated 100 times. The results of these analyses,
including average accuracy, are shown in Table 2. For
the three genes with the highest accuracy (IL2RB,
Figure 1 The workflow to identify genes co-expressed with ZAP70 in multiple cancer datasets using co-expression network analysis.
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using aggregate features by testing two feature combina-
tions. For each aggregate feature, the same test was con-
ducted with the same setting as done on individual
genes. We also examined the sub-cellular locations of
each individual gene. Interestingly, most of the genes
code for membrane proteins, which is a potential advan-
tage for candidate biomarkers, since they can facilitate
detection via effective and fast procedures such as flow
cytometry.
Selecting gene features using mRMR
As indicated in the method section, we also used the
mRMR webtool (http://penglab.janelia.org/proj/mRMR/)
to select genes which form a broad feature set to differ-
entiate the two groups. Specifically, we input the expres-
sion values of all the 51 genes and selected the setting
with mutual information difference scheme based upon
ten features (Table 3).
Table 2 and Table 3 have five genes in common:
IL2RB, LAG3, CD8A, KLRK1 and ZAP70. Furthermore,
Figure 2 The connectivity graph for Network 17. The connectivity ratio r for this network is 0.4142. The names with circle are the genes
which product known to interact with ZAP70.
Figure 3 The top 10 enriched biological functions of Network 17 genes using IPA.
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relatively high predictive capacity for IgVH status, which
suggests that IL2RB and CD8A are potential prognostic
biomarkers besides ZAP70. In addition, CD247, KLRK1
and LAG3 are also good candidate biomarkers for CLL
prognosis due to their high predicting accuracy as well
as their representing distinct features between different
IgVH mutational groups. LAG3 has recently been identi-
fied as a potential CLL prognostic biomarker in another
experimental study[13].
Validate the prognostic capability of the identified
biomarkers using new CLL microarray dataset (GSE10138)
Figure 4 shows the Kaplan-Meier curves of patient time-
to-treatment (TTT) from microarray data (GSE10138) of
61 CLL patients, using ZAP70 and all above identified
biomarker candidates as features to categorize the
patients into two risk groups. TTT is the time point
when the disease evolves from indolent stage into pro-
gressive stage, signifying the switch from low to higher
risk group, therefore is a suitable parameter to test our
biomarkers for prognosis. The above biomarker candi-
dates clearly separated the patients into two risk groups
using the K-means algorithm (K=2), with the log-rank
test p-value as low as 0.033. However, if only using
ZAP70 as the feature to separate the patients, the differ-
ence of TTT between the two groups is not significant
(log-rank test p > 0.05, figure not shown). Interestingly,
with or without KLRK1, the patient grouping results
and p-values stay the same.
Discussion
As shown in Figure 5, except for KLRK1, all above bio-
marker candidates have been known to interact with
each other and/or with ZAP70. Here we discuss the
potential of the selected genes based on literature survey
and our results:
Table 1 Statistics of comparison between the IgVH unmutated and mutated groups for Network 17 genes
Genes p-values (Unmutated vs Mutated IgVH) Mean fold change (Unmutated vs Mutated IgVH) p-value
(Patients vs Normal)
SH2D1A 1.3E-3 1.944 0.089
IL2RB 8.1E-5 1.821 4.8E-16
KLRK1 4.9E-3 1.813 0.0079
CD247 1.6E-4 1.807 7.1E-8
GZMB 3.1E-3 1.719 6.2E-11
CD3G 0.017 1.685 0.41
CD3D 1.4E-4 1.621 4.3E-16
GZMK 0.022 1.586 9.2E-11
CD8A 9.9E-5 1.576 3.5E-9
NKG7 8.3E-4 1.560 1.3E-9
ZAP70 7.9E-4 -1.403 5.5E-12
LAG3 0.023 -1.598 0.028
The p-values are the results of Student’s t-test of comparing the IgVH mutated vs. unmutated group, as well as comparing the CLL patient vs. normal group.
Table 2 Accuracy of predicting IgVH mutational status
with individual / combined potential biomarkers
Genes Prediction Accuracy Sub-cellular location
SH2D1A 57.32% cytoplasmic
IL2RB 68.84% membrane
KLRK1 63.67% membrane
CD247 66.03% membrane
GZMB 57.13% secreted
CD3G 62.52% membrane
CD3D 64.27% membrane
GZMK 57.58% secreted
CD8A 68.31% membrane
NKG7 64.94% membrane
ZAP70 68.46% cytoplasmic
LAG3 59.53% membrane
ZAP70+IL2RB 73.22% -
ZAP70+IL2RB+CD8A 74.62% -
The names with bold letter indicate predicting accuracy above 65%. A linear
classifier was used. The cross-validation was carried out with 20% holdout.
Each test was carried out independently.
Table 3 The top ten genes selected by mRMR ordered by
the mRMR score
Order Name mRMR Score
1 IL2RB 0.101
2 LAG3 0.020
3 RASGRP1 0.029
4 CD8A 0.021
5 XCL1 0.011
6 ZAP70 0.018
7 CD79A 0.001
8 FMNL1 0.000
9 KLRK1 0.000
10 CST7 0.002
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Page 5 of 9LAG3 (lymphocyte-activation gene 3): LAG3 product
is involved in T-cell-dependent B-cell activation. It has
been shown to be a potential biomarker using experi-
mental methods in a recent study [13]. This observation
not only partially validated our approach for identifying
prognostic biomarkers for CLL, but also suggested that
our method is able to identify even better biomarker,
given that IL2RB and CD8A have stronger predictive
power than LAG3.
IL2RB (interleukin 2 receptor subunit beta): Expres-
sion of the IL2 receptor subunits IL2RB and IL2RG on
B-cells has been known to be a sign of CLL [15,16].
Various drugs have been designed to target IL2 in CLL,
even though it is not clear why some patients show
relapse after the treatment [ 1 7 ] .H o w e v e r ,c u r r e n t l yw e
are not aware of any study relating IL2RB with IgVH
mutation status. Our results suggest that IL2RB has a
great potential of being a prognostic biomarker for CLL.
CD8AandCD247: Both are T-cell surface antigens,
but expression of CD8A on B-cells has been reported in
CLL patients [18,19]. Since the samples for the data in
GDS1454 are generated from mononuclear cells includ-
ing both T-cells and B-cells, it is not clear what the ori-
gin of these molecules is. Regardless, they demonstrate
comparable capacity in predicting IgVH mutation status
as ZAP70 and are worthy of further investigation.
KLRK1 (killer cell lectin-like receptor superfamily K,
member 1): KLRK1 is also called CD314. It is a member
of C-type lectin-like family of type II cell surface glyco-
proteins, which is expressed by NK cells, CD8+ cells and
certain types of T-cells [20]. KLRK1 is involved in trans-
mitting activation signals into these types of cells, but it
has never been associated with CLL or its prognosis.
There is no known interaction between KLRK1 and
other known or prognostic biomarkers identified in this
paper, as indicated by its absence from the network
Figure 4 The Kaplan-Meier curves of the two groups of CLL patients in the dataset GSE10138 using unsupervised K-mean clustering.
The biomarkers used to generate the survival curves are: ZAP70, LAG3, IL2RB, CD247, CD8A and KLRK1.
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5 ) .I ti ss p e c u l a t e dt h a tt h ee x p r e s s i o nl e v e lc h a n g ei n
KLRK1 is probably a secondary effect of one or more of
the rest of the biomarkers candidates, therefore whether
including it or not seems not to affect the prognosis
results.
In this paper, we employed the CODENSE algorithm
to identify 44 gene co-expression networks using 23
cancer datasets. We found that the co-expression net-
work containing ZAP70 is enriched with genes that
show differential expression between the IgVH unmu-
tated and mutated groups, even though there is no CLL
data included in the original 23 datasets from which the
network was constructed. This finding suggests that the
co-expression networks identified in this study can serve
as a set of generic building blocks for biomarker selec-
tion and gene interaction in cancer studies[22].
A key issue in biomarkers discovery is to choose the
candidates for experimental validation from vast amount
of potential genes. Here we show that gene co-expres-
sion network analysis is an effective method for narrow-
ing down the list of candidates. However, there are two
limitations to this approach that should be noted: First,
the effectiveness of this approach has not been deter-
mined by a prospective experimental study; and second,
the approach is based on known biomarkers and may
miss novel markers that involve in different mechanisms
or regulation pathways. Therefore, currently we plan to
Figure 5 The known interactions among potential prognostic biomarkers and ZAP70. The interactions were extracted from Ingenuity
Pathway Knowledge database. The abbreviations for interaction types: A: activation; L: proteolysis; M: biochemical modification;
P: phosphorylation/dephosphorylation; LO: localization; MB: group/complex membership; PP: protein-protein binding; RB: regulation of binding.
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have been identified using CODENSE. Another direction
for the future study is to explore aggregate biomarkers
of a combined group of gene products. We demon-
strated the feasibility of this approach in Table2. How-
ever, a more rigorous and systematic screening for
different combinations of genes is needed, which is part
of our ongoing study.
Conclusions
Using frequent gene co-expression analysis, we have
identified a set of genes, IL2RB, CD8A, CD247, LAG3
and KLRK1, which are potential CLL prognostic bio-
markers. Their prognostic capabilities were cross-vali-
dated by applying these biomarkers to classify patient
survival groups using a CLL microarray datasets with
patient clinical outcome information.
Methods
Data selection
We initiated this project by querying the GEO data-
base using the term “chronic lymphocytic leukemia”
[21]. Five GDS dataset results were returned from the
query: GDS2676, GDS2643, GDS2501, GDS1454, and
GDS1388. We filtered these results to identify datasets
comparing patients in different groups; yielding the
GDS1454 and GDS1388 data sets. GDS1454 is particu-
l a r l yi m p o r t a n ts i n c ei tc o n t a i n sd a t ao b t a i n e df r o m
the mononuclear cells of 111 subjects (11 normal sub-
jects, 49 CLL patients without IgVH mutation, and 51
CLL patients with IgVH mutations). These GDS data-
sets were downloaded for analysis. In addition, a
recently available CLL microarray dataset GSE10138
containing 68 patients was used to validate the biomar-
kers identified in the paper. Among them, the clinical
information for 61 patients (33 with stable CLL and 28
with progressive disease) is available, and used in vali-
dation step.
Co-Expression network discovery using CODENSE
As described earlier, we have previously used gene co-
expression network analysis to identify novel biomarkers
for breast cancer [22]. We applied a similar method in
this project. In our approach, GEO was queried using
terms “metastatic cancer”. Then only the datasets (GDS
data) containing both normal and tumor tissues
obtained from primary flash frozen biopsy (cell lines
and secondary cultures were excluded) were selected.
Using this method, 23 datasets from 15 types of cancer
were selected. The Pearson correlation coefficients
(PCC) for every pair of genes in every dataset were com-
puted. Since we focus on gene pairs that are highly cor-
related, for each dataset we retained the gene pairs with
|PCC| being 0.75 or higher.
The CODENSE algorithm was originally developed for
identifying gene networks in multiple microarray data-
sets and is therefore suitable for our study [23]. We
applied the CODENSE algorithm to the 23 lists of
selected gene pairs as described above such that net-
works were constructed from gene pairs that appeared
in at least 4 datasets. The networks with connectivity
ratios r > 0.4 (i.e., given a co-expression network with
K nodes and L edges, r=L /(K(K-1)/2)) were selected
for further analysis.
Test selected genes on a CLL dataset (GDS1454) using
supervised methods
For the genes in the co-expression networks that included
ZAP70, we further selected a subset of genes as potential
prognosis markers for CLL by identifying genes whose
expression levels can predict IgVH mutation status. Out of
the 51 genes from network 17, only 40 were present in the
GDS1454 dataset, therefore only these 40 genes were
examined in the following steps. Our approach to doing
so includes three steps (also see Figure 1):
1. We compared their expression levels between the
49 patients without IgVH mutation and the 51 patients
with IgVH mutations in GDS1454 and selected genes
which demonstrated significant differential expression
between the two groups.
2. The genes selected in step 1 were further tested for
their capability of predicting IgVH mutation status using a
supervised linear classifier (as described in [24] and imple-
mented in the classify function in Matlab which fit normal
distributions to the groups) and a cross validation with
20% sample holdout, which is then repeated 100 times.
3. In addition to the tests on individual genes, we also
applied a feature selection method, mRMR (minimum
Redundancy Maximum Relevance), to select a group of
feature genes from the gene list that can differentiate
the two group patients. The mRMR was originally
designed for gene selection in microarray data [25]. It
allows us to select a subset of genes that can effectively
distinguish the two groups of subjects (IgVH unmutated
vs. IgVH mutated).
Cross-validate the prognostic biomarkers with CLL
dataset (GSE10138)
Unsupervised K-mean clustering (K=2) was performed
100 times (to ensure convergence and avoid local opti-
mal results) on CLL microarray dataset GSE10138 using
the expression levels of ZAP70, IL2RB, CD8A, CD247,
LAG3 and KLRK1 as features. The dataset GSE10138
also contains the time-to-treatment (TTT) information
for 61 patients, which is used to plot the Kaplan-Meier
curves. Log-rank test was performed to determine the
p-value of difference in TTT between the two patient
groups.
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Page 8 of 9GO-term enrichment and pathway analysis using IPA
A commercially available pathway analysis package Ingenu-
ity Pathway Analysis (IPA) was used to search the known
interactions between identified biomarkers as well as to
study the GO-term enrichment of the identified networks.
Query other gene interaction database
To compare our results relative to ZAP70 gene co-
expression with genes that are known interactants with
ZAP70, we search for functional protein association in
the GeneCards database (http://www.genecards.org/).
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